260 related articles for article (PubMed ID: 31500517)
21. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
22. A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia.
Bryant A; Sheppard D; Sabloff M; Delbaere M; Maze R; Allan D; Atkins H; Bence-Bruckler I; Faught C; Huebsch L; Tay J; Zanke B; Bredeson C
Leuk Lymphoma; 2015 Jan; 56(1):135-40. PubMed ID: 24913512
[TBL] [Abstract][Full Text] [Related]
23. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines.
Specchia G; Buquicchio C; Pansini N; Di Serio F; Liso V; Pastore D; Greco G; Ciuffreda L; Mestice A; Liso A
J Lab Clin Med; 2005 Apr; 145(4):212-20. PubMed ID: 15962840
[TBL] [Abstract][Full Text] [Related]
25. Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines.
Peddi P; Master SR; Dwary AD; Ravipati HP; Patel AH; Pasam A; Katikaneni PK; Shi R; Burton GV; Chu QD
Breast J; 2019 Jan; 25(1):62-68. PubMed ID: 30592128
[TBL] [Abstract][Full Text] [Related]
26. Cardiac toxicity after anthracycline chemotherapy in childhood.
Iarussi D; Indolfi P; Galderisi M; Bossone E
Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience.
Mo Z; Deng Y; Bao Y; Liu J; Jiang Y
Cancer Med; 2023 Dec; 12(24):21709-21724. PubMed ID: 38054208
[TBL] [Abstract][Full Text] [Related]
28. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
Khan AA; Ashraf A; Singh R; Rahim A; Rostom W; Hussain M; Renner I; Collins NJ
Intern Med J; 2017 Jan; 47(1):104-109. PubMed ID: 27800661
[TBL] [Abstract][Full Text] [Related]
29. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
[TBL] [Abstract][Full Text] [Related]
30. Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients.
Zhou X; Weng Y; Jiang T; Ou W; Zhang N; Dong Q; Tang X
BMC Cancer; 2023 Oct; 23(1):976. PubMed ID: 37833648
[TBL] [Abstract][Full Text] [Related]
31. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of cardiotoxicity by tissue Doppler imaging in childhood leukemia survivors treated with low-dose anthracycline.
Bayram C; Çetin İ; Tavil B; Yarali N; Ekici F; Isık P; Tunc B
Pediatr Cardiol; 2015 Apr; 36(4):862-6. PubMed ID: 25577226
[TBL] [Abstract][Full Text] [Related]
33. Anthracyclines in a patient with acute leukemia and severe cardiomyopathy requiring mechanical support: A case report.
Banerjee R; Lo M; Klein L; Aras M; Logan AC
J Oncol Pharm Pract; 2022 Apr; 28(3):729-732. PubMed ID: 34846217
[TBL] [Abstract][Full Text] [Related]
34. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
[TBL] [Abstract][Full Text] [Related]
35. [Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses].
Lemez P; Stejskal J; Cahová S; Holub M; Svítil P; Maresová J; Vásová I; Boudová L; Benesová V; Dvoráková D; Fisar J; Slavícek L
Vnitr Lek; 2004 Jun; 50(6):438-46. PubMed ID: 15346637
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom.
Temming P; Qureshi A; Hardt J; Leiper AD; Levitt G; Ancliff PJ; Webb DK
Pediatr Blood Cancer; 2011 Apr; 56(4):625-30. PubMed ID: 21298750
[TBL] [Abstract][Full Text] [Related]
37. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Dodos F; Halbsguth T; Erdmann E; Hoppe UC
Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
[TBL] [Abstract][Full Text] [Related]
39. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
40. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
